Pascal Touchon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pascal touchon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pascal Touchon Today - Breaking & Trending Today

Atara Biotherapeutics (NASDAQ:ATRA) Given Neutral Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2024 earnings at $0.06 EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings […] ....

United States , Anhco Nguyen , Pascal Touchon , Harbor Capital Advisors Inc , Atara Biotherapeutics Inc , Vontobel Holding Ltd , Advisor Group , Josh Arnold Investment Consultant , Atara Biotherapeutics Company Profile , Delap Wealth Advisory , Free Report , Get Free Report , Wealth Advisory , Arnold Investment Consultant , Harbor Capital Advisors , Capital Advisors ,

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Post Q1 2025 Earnings of ($0.27) Per Share

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Free Report) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Atara Biotherapeutics in a research note issued on Wednesday, May 22nd. HC Wainwright analyst R. Burns expects that the biotechnology company will post earnings of ($0.27) per share for the quarter. […] ....

United States , Anhco Nguyen , Pascal Touchon , Advisor Group , Atara Biotherapeutics Company Profile , Securities Exchange Commission , Harbor Capital Advisors Inc , Delap Wealth Advisory , Vontobel Holding Ltd , Atara Biotherapeutics Inc , Free Report , Get Free Report , Exchange Commission , Wealth Advisory , Capital Advisors , Financial Markets ,

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Pascal Touchon Sells 81,506 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) CEO Pascal Touchon sold 81,506 shares of the firm’s stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $0.62, for a total transaction of $50,533.72. Following the completion of the sale, the chief executive officer now owns 1,829,146 shares […] ....

United States , Pascal Touchon , Vontobel Holding Ltd , Harbor Capital Advisors Inc , Delap Wealth Advisory , Atara Biotherapeutics Inc , Advisor Group , Sg Americas Securities , Get Free Report , Wealth Advisory , Capital Advisors , Private Advisor Group ,

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration

If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD

Acceptance of BLA Will Trigger $20. ....

United States , Pascal Touchon , Pierre Fabre , Securities Exchange , Memorial Sloan Kettering Cancer Center , Atara Biotherapeutics Inc , Exchange Commission , Drug Administration , Biologics License Application , Chief Executive Officer , Objective Response Rate , Securities Act , Securities Exchange Act , Pierre Fabre Laboratories , Middle East , Southern California , Financial Condition ,

ATARA Biotherapeutics (ATRA) Submits Tabelecleucel BLA for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

ATARA Biotherapeutics (ATRA) Submits Tabelecleucel BLA for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Pierre Fabre , Pascal Touchon , Drug Administration , Healthcare Products Regulatory Agency , Atara Biotherapeutics Inc , Memorial Sloan Kettering Cancer Center , European Commission , Biologics License Application , Chief Executive Officer , Objective Response Rate , Breakthrough Therapy Designation , Pierre Fabre Laboratories , Middle East ,